La Jolla Pharmaceutical Company [NASDAQ: LJPC] closed the trading session at $5.04 on 01/12/21. The day’s price range saw the stock hit a low of $4.86, while the highest price level was $6.24. The company report on January 12, 2021 that La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe.
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) in the European Economic Area, the United Kingdom and Switzerland (the Territories).
The stocks have a year to date performance of 29.90 percent and weekly performance of 26.95 percent. The stock has been moved at 18.03 percent over the last six months. The stock has performed 11.26 percent around the most recent 30 days and changed 20.57 percent over the most recent 3-months.
If compared to the average trading volume of 237.74K shares, LJPC reached to a volume of 36876665 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about La Jolla Pharmaceutical Company [LJPC]:
H.C. Wainwright have made an estimate for La Jolla Pharmaceutical Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 26, 2019. The new note on the price target was released on November 25, 2019, representing the official price target for La Jolla Pharmaceutical Company stock.
The Average True Range (ATR) for La Jolla Pharmaceutical Company is set at 0.38, with the Price to Sales ratio for LJPC stock in the period of the last 12 months amounting to 4.68.
LJPC stock trade performance evaluation
La Jolla Pharmaceutical Company [LJPC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.95. With this latest performance, LJPC shares gained by 11.26% in over the last four-week period, additionally plugging by 18.03% over the last 6 months – not to mention a drop of -28.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LJPC stock in for the last two-week period is set at 65.91, with the RSI for the last a single of trading hit 72.47, and the three-weeks RSI is set at 61.77 for La Jolla Pharmaceutical Company [LJPC]. The present Moving Average for the last 50 days of trading for this stock 4.35, while it was recorded at 4.26 for the last single week of trading, and 4.80 for the last 200 days.
La Jolla Pharmaceutical Company [LJPC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and La Jolla Pharmaceutical Company [LJPC] shares currently have an operating margin of -455.02 and a Gross Margin at +64.21. La Jolla Pharmaceutical Company’s Net Margin is presently recorded at -505.37.
Return on Total Capital for LJPC is now -81.36, given the latest momentum, and Return on Invested Capital for the company is -91.34. Additionally, LJPC Total Debt to Total Capital is recorded at 157.35, with Total Debt to Total Assets ending up at 116.17.
Reflecting on the efficiency of the workforce at the company, La Jolla Pharmaceutical Company [LJPC] managed to generate an average of -$1,280,308 per employee. Receivables Turnover for the company is 10.62 with a Total Asset Turnover recorded at a value of 0.14.La Jolla Pharmaceutical Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.20.
Earnings per share (EPS) analysis for La Jolla Pharmaceutical Company [LJPC] stock
With the latest financial reports released by the company, La Jolla Pharmaceutical Company posted -0.93/share EPS, while the average EPS was predicted by analysts to be reported at -0.95/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LJPC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for La Jolla Pharmaceutical Company go to 13.20%.
La Jolla Pharmaceutical Company [LJPC]: Insider Ownership positions
There are presently around $80 million, or 78.20% of LJPC stock, in the hands of institutional investors. The top three institutional holders of LJPC stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 9,405,490, which is approximately 8.165% of the company’s market cap and around 0.20% of the total institutional ownership; RTW INVESTMENTS, LP, holding 2,395,029 shares of the stock with an approximate value of $9.44 million in LJPC stocks shares; and BLACKROCK INC., currently with $5.68 million in LJPC stock with ownership of nearly -3.491% of the company’s market capitalization.
Positions in La Jolla Pharmaceutical Company stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 21 institutional holders increased their position in La Jolla Pharmaceutical Company [NASDAQ:LJPC] by around 1,677,457 shares. Additionally, 41 investors decreased positions by around 1,501,034 shares, while 17 investors held positions by with 17,186,919 shares. The mentioned changes placed institutional holdings at 20,365,410 shares, according to the latest SEC report filing. LJPC stock had 4 new institutional investments in for a total of 284,405 shares, while 16 institutional investors sold positions of 790,028 shares during the same period.